Peregrine Announces Preliminary Results From Phase II Brain Cancer Trial (Business Wire)Peregrine Pharmaceuticals Inc. today announced Dr. Sunil Patel, associate professor of neurosurgery at the Medical University of South Carolina, presented preliminary efficacy and safety results from a Phase II brain cancer trial using Cotara(TM), Peregrine`s Tumor Necrosis Therapy drug.- May 14 3:30 PM ET

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source:

(Everything below this line is from!)

Click HERE to return to brain tumor news headlines.